Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Enterprise Value (2016 - 2025)

Protalix BioTherapeutics has reported Enterprise Value over the past 16 years, most recently at -$16.3 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$16.3 million for Q4 2025, down 8.13% from a year ago — trailing twelve months through Dec 2025 was -$16.3 million (down 8.13% YoY), and the annual figure for FY2025 was -$16.3 million, down 8.13%.
  • Enterprise Value for Q4 2025 was -$16.3 million at Protalix BioTherapeutics, up from -$29.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for PLX hit a ceiling of -$15.1 million in Q4 2024 and a floor of -$76.9 million in Q2 2021.
  • Median Enterprise Value over the past 5 years was -$34.1 million (2025), compared with a mean of -$37.8 million.
  • Biggest five-year swings in Enterprise Value: tumbled 119.89% in 2021 and later soared 66.18% in 2024.
  • Protalix BioTherapeutics' Enterprise Value stood at -$39.0 million in 2021, then soared by 43.11% to -$22.2 million in 2022, then tumbled by 100.9% to -$44.6 million in 2023, then soared by 66.18% to -$15.1 million in 2024, then fell by 8.13% to -$16.3 million in 2025.
  • The last three reported values for Enterprise Value were -$16.3 million (Q4 2025), -$29.4 million (Q3 2025), and -$33.4 million (Q2 2025) per Business Quant data.